GLA and Fabry disease: For example, patients with Fabry disease can be treated either with enzyme replacement therapy (ERT; available since 2001) [24, 25] or, in case of amenable pathogenic galactosidase alpha (GLA) gene variants, with a pharmacological chaperone therapy (available since 2016) [26, 27].